Nicole L Lebo1, Rebecca Griffiths2, Stephen Hall2,3, Jim Dimitroulakos4, Stephanie Johnson-Obaseki1. 1. Department of Otolaryngology - Head and Neck Surgery, University of Ottawa, Ottawa, Ontario, Canada. 2. Institute for Clinical Evaluative Sciences - Queen's, Queen's University, Kingston, Ontario, Canada. 3. Department of Otolaryngology - Head and Neck Surgery, Queen's University, Kingston, Ontario, Canada. 4. Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Abstract
BACKGROUND: Preclinical and early-phase clinical studies have suggested an oncoprotective role of statins in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to determine whether incidental statin use in patients with human papillomavirus (HPV)-negative HNSCC is predictive of improved oncologic outcomes. METHODS: A retrospective cohort study of 1194 patients from the Ontario Cancer Registry diagnosed with HNSCC from 2007 to 2012 was performed using linked databases from the Institute for Clinical Evaluative Sciences. Overall survival (OS) and disease-specific survival (DSS) were compared between patients taking statins and controls. RESULTS: Patients with statin exposure demonstrated improved OS (hazard ratio [HR] 0.758; P = .0011; 95% confidence interval [CI] 0.642-0.896), and DSS (HR 0.693; P = .0040; 95% CI 0.539-0.889) compared with those not on statins at the time of diagnosis. CONCLUSION: Incidental statin use at the time of diagnosis of HPV-negative squamous cell carcinoma (SCC) of the larynx, hypopharynx, and nasopharynx demonstrated improved OS and DSS.
BACKGROUND: Preclinical and early-phase clinical studies have suggested an oncoprotective role of statins in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to determine whether incidental statin use in patients with human papillomavirus (HPV)-negative HNSCC is predictive of improved oncologic outcomes. METHODS: A retrospective cohort study of 1194 patients from the Ontario Cancer Registry diagnosed with HNSCC from 2007 to 2012 was performed using linked databases from the Institute for Clinical Evaluative Sciences. Overall survival (OS) and disease-specific survival (DSS) were compared between patients taking statins and controls. RESULTS:Patients with statin exposure demonstrated improved OS (hazard ratio [HR] 0.758; P = .0011; 95% confidence interval [CI] 0.642-0.896), and DSS (HR 0.693; P = .0040; 95% CI 0.539-0.889) compared with those not on statins at the time of diagnosis. CONCLUSION: Incidental statin use at the time of diagnosis of HPV-negative squamous cell carcinoma (SCC) of the larynx, hypopharynx, and nasopharynx demonstrated improved OS and DSS.
Authors: Abhinav Gupta; William Stokes; Megan Eguchi; Mohammad Hararah; Arya Amini; Adam Mueller; Rustain Morgan; Cathy Bradley; David Raben; Jessica McDermott; Sana D Karam Journal: Oral Oncol Date: 2019-02-04 Impact factor: 5.337
Authors: Katharine Fernandez; Katie K Spielbauer; Aaron Rusheen; Lizhen Wang; Tiffany G Baker; Stephen Eyles; Lisa L Cunningham Journal: Hear Res Date: 2020-02-06 Impact factor: 3.208
Authors: Kayla R Getz; Emily Bellile; Katie R Zarins; Cailey Rullman; Steven B Chinn; Jeremy M G Taylor; Laura S Rozek; Gregory T Wolf; Alison M Mondul Journal: Int J Cancer Date: 2020-12-15 Impact factor: 7.316
Authors: Manal Mehibel; Fernando Ortiz-Martinez; Nadine Voelxen; Amy Boyers; Amy Chadwick; Brian A Telfer; Wolfgang Mueller-Klieser; Catharine M West; Susan E Critchlow; Kaye J Williams; Ian J Stratford Journal: Sci Rep Date: 2018-11-14 Impact factor: 4.379
Authors: Alexandra E Quimby; Nicole L Lebo; Rebecca Griffiths; Stephen Hall; Jim Dimitroulakos; Stephanie Johnson-Obaseki Journal: J Otolaryngol Head Neck Surg Date: 2018-12-04